亞輝龍(688575.SH)獲兩項軟件著作權:胰島功能標化評估系統助力糖尿病精準診療
格隆匯3月16日丨亞輝龍(688575.SH)發佈公告,公司於近日取得了由國家版權局頒發的兩項計算機軟件著作權登記證書。軟件名稱爲:胰島功能標化評估系統(Web 端)[簡稱: multipif-web]V1.0;以及胰島功能標化評估小程 序 [ 簡稱: multipif-mp]V1.0。
胰島功能標化評估系統軟件是由亞輝龍聯合江蘇省人民醫院、南京醫科大學,共同研發的一款胰島功能標化評估數智平臺,其基於大規模臨牀數據和機器學習算法,創新性地讓糖尿病人及醫生使用現有臨牀檢驗結果,計算並動態監測患者的胰島功能,減少人爲因素的幹擾,提升臨牀診斷效率和準確性,讓數智真正爲醫患服務,成功打通診療 “關鍵環節”。該系統對於糖尿病等代謝性疾病的分型診斷、治療方案制定和隨訪觀察具有重要意義,能夠有效提升患者的治療效果、改善糖尿病的預後。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.